Mpox vaccine allocation targets 9 African countries

The Access and Allocation Mechanism (AAM) for mpox has allocated an initial 899 000 vaccine doses for 9 countries across the African region that are hit hard by the current mpox surge. In collaboration with affected countries and donors, this decision aims to ensure that the limited doses are used effectively and fairly, with the overall objective to control the outbreaks.

The AAM principals from the Africa Centres for Disease Control and Prevention (Africa CDC), the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi), UNICEF, and the World Health Organization (WHO) approved the allocation, following the recommendations of an independent Technical Review Committee of the Continental Incident Management Support Team for mpox. The decision was informed by country readiness and epidemiological data.

The 9 countries are the Central African Republic, Cote d'Ivoire, the Democratic Republic of the Congo, Kenya, Liberia, Nigeria, Rwanda, South Africa and Uganda. The largest number of doses – 85% of the allocation – will go to the Democratic Republic of the Congo as the most affected country, reporting four out of every five laboratory-confirmed cases in Africa this year.

These doses come from Canada, Gavi, the Vaccine Alliance, the European Union (Austria, Belgium, Croatia, Cyprus, France, Germany, Luxemburg, Malta, Netherlands, Poland, Portugal and Spain, as well as the European Union Health Emergency Response Authority), and the Unites States of America.

The outbreak of mpox, particularly the surge of the viral strain clade Ib, in the Democratic Republic of the Congo and neighbouring countries was declared a public health emergency of international concern by WHO and a public health emergency of continental security by Africa CDC in mid-August. This year, 19 countries in Africa have reported mpox, many of them newly affected by the viral disease. The epicentre of the outbreak remains the Democratic Republic of the Congo, with over 38 000 suspected cases and over 1000 deaths reported this year.

Vaccination is recommended as a part of a comprehensive mpox response strategy, focusing also on timely testing and diagnosis, effective clinical care, infection prevention, and the engagement of affected communities. Vaccines play an important role and are recommended to reduce transmission and help contain outbreaks.

In recent weeks, limited vaccination has begun in the Democratic Republic of the Congo and Rwanda. This allocation to the 9 countries marks a significant step towards a coordinated and targeted deployment of vaccines to stop the mpox outbreaks.

For most countries, the rollout of mpox vaccines will be a new undertaking. Implementing targeted vaccination requires additional resources. Partners of the mpox AAM, set up last month, are working to scale up the response. Further allocations of vaccines are expected before the end of the year.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
WHO grants Emergency Use Listing for LC16m8 mpox vaccine